Bristol Myers to present data at ESMO on immuno-oncology, progression of assets

Bristol Myers Squibb announced the presentation of nearly 60 abstracts of company-sponsored studies, investigator-sponsored studies, and collaborations from across its oncology portfolio and pipeline at the European Society for Medical Oncology Congress 2024 to be held from September 13-17 in Barcelona, Spain. Key data being presented by Bristol Myers Squibb at ESMO Congress 2024 include: Data supporting our innovative oncology portfolio: Ten-year follow-up data from the Phase 3 CheckMate -067 trial showed the continued durable, long-term survival benefit of Opdivo plus Yervoy in patients with advanced or metastatic melanoma. These data represent the longest reported median overall survival from a Phase 3 advanced melanoma trial. An update of clinical outcomes from the Phase 3 CheckMate -77T trial evaluating an Opdivo-based perioperative regimen in patients with resectable non-small cell lung cancer. Expanded analyses from the CheckMate -9DW trial evaluating Opdivo plus Yervoy vs lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma. Subgroup efficacy and expanded safety data from the Phase 3 CheckMate -8HW trial evaluating Opdivo plus Yervoy as first-line treatment for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer. Updated efficacy and safety results at approximately 15-months of follow up from the Phase 3 CheckMate -67T trial evaluating subcutaneous nivolumab in patients with previously treated advanced or metastatic clear cell renal cell carcinoma. Efficacy and safety data from the randomized Phase 3 KRYSTAL-12 trial evaluating KRAZATI versus docetaxel in patients with pretreated locally advanced or metastatic NSCLC harboring a KRASG12C mutation and baseline brain metastases. Studies supporting our advancing pipeline: Data from the proof-of-concept, randomized, Phase 2 RELATIVITY-104 trial evaluating the combination of nivolumab and relatlimab plus platinum-doublet chemotherapy as first-line treatment for stage IV or recurrent NSCLC. BMS is initiating the Phase 3 RELATIVITY-1093 trial evaluating the fixed-dose combination of nivolumab and relatlimab plus chemotherapy versus pembrolizumab plus chemotherapy as a first-line treatment for patients with stage IV or recurrent non-squamous NSCLC with tumor cell PD-L1 expression of 1 to 49%, supported by findings from the RELATIVITY-104 trial. First data from the randomized, Phase 2 CA001-050 trial evaluating BMS-986012, an anti-fucosyl-GM1 monoclonal antibody, in combination with carboplatin, etoposide, and nivolumab as a first-line therapy in newly diagnosed patients with extensive-stage small cell lung cancer: interim analysis. Updated safety and clinical activity from first-in-human Phase 1 trial evaluating the targeted protein degrader BMS-986365, the company’s potential best-in-class oral dual androgen receptor ligand-directed degrader and antagonist, in heavily pre-treated patients with metastatic castration-resistant prostate cancer. Three presentations of data evaluating BL-B01D1, a bispecific antibody-drug conjugate targeting both EGFR and HER3 being developed in collaboration with SystImmune, Inc., in locally advanced or metastatic biliary tract cancer, locally advanced or metastatic urothelial carcinoma, and locally advanced or metastatic esophageal squamous cell carcinoma.